NorthWest Biotherapeutics Inc (NWBO)

[f3tt3f]

Much like how others have interpreted the PR - I read is it being as positive as can be, without actually stating a halt for efficacy.

- They were compelled by shareholders to ask the DMC for an update.

- The DMC hadn't completed their review of the data, but were happy to recommend a continue with the data at hand. i.e They are satisfied that there is no safety or futility risk (otherwise they would not have given the decision to continue).

- If there wasn't the possibility of an early halt for efficacy they would have simply said it was a continue (and nothing else, like the vast majority interim 'continue' decisions)

- The extra color added with their statement: "The DSMB's review of the efficacy data is still pending." was put in for a reason.
That reason, I believe, was to infer that efficacy data is encouraging enough to warrant further deliberation.